Bolus Versus Continuous Remimazolam for Anesthetic Induction

Kangbuk Samsung Hospital

Status: Not yet enrolling

Conditions: Hypotension on Induction

Treatments: Drug: Remimazolam continuous; Drug: Remimazolam bolus

Study type: Interventional

Funder types: Other

Identifiers

NCT05536323

RMZ_bolcon

Details and patient eligibility

About

Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. For anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion.

This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.

Enrollment: 62 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• scheduled for elective surgery under general anesthesia
• adult patient (over 19 years old)
• American Society of Anesthesiology Physical Status I-III

Exclusion criteria

• arrythmia
• liver dysfunction
• kidney dysfunction
• uncontrolled hypertension
• uncontrolled diabetes mellitus
• allergic to benzodiazepines
• heart failure
• drug intoxication
• alcohol intoxication

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

62 participants in 2 patient groups

Bolus

Experimental group

Description:

Anesthetic induction with bolus remimazolam administration

Treatment:

Drug: Remimazolam bolus

Continuous

Experimental group

Description:

Anesthetic induction with continuous remimazolam administration

Treatment:

Drug: Remimazolam continuous